Mainz Biomed reports increased demand for improved ColoAlert and existing partners are switching to the new version

GANZIMMUN Diagnostics presents ColoAlert at the 57th Baden-Baden Medical Week

BERKELEY, Calif. and MAINZ, Germany, Oct. 8, 2024 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetic diagnostics company specializing in the early detection of cancer, today announced increasing demand from existing and potential laboratory partners for its enhanced ColoAlert product, launched in July 2024 and is currently being marketed across Europe and in select international markets. This advanced version of the Company’s colorectal cancer (CRC) early detection test is intended to become the standard offering for all existing partners and reflects its proven benefits in optimizing screening efficiency and improving user experience.

Comprehensive transition to Enhanced ColoAlert

One of the first partners to make the transition is GANZIMMUN Diagnostics, one of Germany’s leading laboratories that has licensed the ColoAlert test. GANZIMMUN will fully implement the expanded version of the innovative DNA biomarker-based screening product by early next year, benefiting from significant improvements in sample processing and usability that have set a new industry benchmark.

Improving customer interest

Partners are particularly impressed by the advanced features, such as the proprietary DNA stabilization buffer that ensures reliable results despite varying sample volumes, and the optimized collection devices that make testing easier for users at home. These innovations have dramatically reduced the need for retesting and provide patients with faster turnaround times, with results available as early as two to three days after samples are received.

Promotion at an important medical event

GANZIMMUN Diagnostics will present the expanded ColoAlert at the 57th Medical Week Baden-Baden, a medical congress in Germany with a focus on complementary medicine, taking place from October 30 to November 3, 2024. This underlines the increasing role of complementary medicine in cancer prevention and early detection. The event provides an ideal platform to promote Mainz Biomed’s innovative DNA-based CRC screening test to medical professionals, integrative medicine practitioners and researchers interested in advanced diagnostic solutions.
“We are pleased to support GANZIMMUN in launching the improved ColoAlert at such a prestigious event,” said Tarrin Khairi-Taraki, VP Commercial Operations at Mainz Biomed. “The 57th Baden-Baden Medical Week offers an excellent opportunity to show how important early detection of colon cancer is and how our innovations make this process more efficient.”

For more information, please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/
Please follow us to stay updated:
LinkedIn
X (formerly Twitter)
Facebook

About GANZIMMUN Diagnostics
GANZIMMUN Diagnostics is one of the leading laboratories in Europe for preventive and complementary medicine. A multidisciplinary team of more than 420 employees works under the direction of the experienced laboratory doctor Dr. med. around 5,500 laboratory orders per day. Patrik Zickgraf. The comprehensive range of diagnostic services, which includes over 4,000 laboratory parameters, includes basic analysis and a variety of innovative tests such as the ColoAlert.

To find out more, visit https://www.ganzimmun.de/en/

About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening diseases. The company’s flagship product is ColoAlert^®an accurate, non-invasive and easy-to-use early detection test for colon cancer. ColoAlert^® is marketed throughout Europe and the United Arab Emirates. The company is currently conducting a pivotal FDA clinical trial for regulatory approval in the United States. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early detection test for pancreatic cancer based on real-time polymerase chain reaction (PCR)-based multiplex detection of molecular genetic biomarkers in stool samples. To find out more, visit mainzbiomed.com or keep following us LinkedIn, Twitter And Facebook.

For media inquiries
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
[email protected]
For investor inquiries please contact [email protected]

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “believes,” “ expect”, “estimate”, “plan”, “outlook” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical fact. These forward-looking statements reflect current analysis of existing information and are subject to various risks and uncertainties. Therefore, caution should be exercised when relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) failure to achieve forecast developments and related objectives; (ii) changes in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein and the risks and uncertainties discussed by the Company from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”). Further information about these and other factors that may affect the Company’s expectations and projections can be found in its initial filings with the SEC, including its Annual Report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are publicly available at the SEC’s website at www.sec.gov. Any forward-looking statements we make in this press release are based solely on information currently available to Mainz Biomed and speak only as of the date hereof. Mainz Biomed undertakes no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time as a result of new information, future developments or otherwise, except as required by law.